Showing 2,798 results

Filters Content type: News, Editors' picks, About HIV Topic: PrEP

Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP).

PrEP programmes & uptake

People Seeking PrEP Face Numerous Nonfinancial Roadblocks

Editor's pick
POZ
25 November 2019
Government, leadership & policy

The World Cannot End HIV Without Continued Innovation

Editor's pick
POZ
25 November 2019
PrEP policies & guidelines

Barring cisgender women from the Descovy trials was a bad call

Editor's pick
STAT
25 November 2019
Treatment interruptions

Second case of unintended HIV transmission during HIV cure study prompts questions about PrEP provision

News
22 November 2019
PrEP programmes & uptake

Intermittent and lower-risk PrEP users may not be testing for HIV and STIs, German study finds

News
22 November 2019
New & experimental HIV treatments

ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational "bNAb" with potential for long-acting HIV treatment and prevention

Editor's pick
ViiV Healthcare press release
21 November 2019
Mental & emotional health & wellbeing

PrEP users have less HIV anxiety

News
21 November 2019
PrEP science

Serosorting between gay men may be in decline as ‘PrEP sorting’ rises, Canadian study finds

News
20 November 2019
Hepatitis C transmission & prevention

Hepatitis C incidence is low among Canadian men on PrEP

News
15 November 2019
PrEP science

How do we deal with apparent cases of PrEP failure?

News
15 November 2019
PrEP science

96-week results of DISCOVER PrEP trial presented at European AIDS Conference

News
14 November 2019
People & personal stories

The Berlin Patient, the First Person Ever Cured of HIV, on Taking PrEP: "I Want a Full Sexual Life"

Editor's pick
TheBodyPro
12 November 2019
HIV prevention policy

Did The CDC's Jonathan Mermin Prevent PrEP Access to the Public?

Editor's pick
HIV Plus
12 November 2019
Pharmaceutical industry

Untangling the Trump administration's lawsuit over an HIV prevention drug

Editor's pick
Science
11 November 2019
PrEP programmes & uptake

French study finds one in six stops PrEP within 12 months, one in three after 30 months

News
11 November 2019
PrEP science

Descovy for PrEP Continues to Be Noninferior to Truvada, According to 96 Week Data

Editor's pick
Monthly Prescribing Reference
8 November 2019
Pharmaceutical industry

U.S. sues drugmaker Gilead over patents on HIV prevention treatment

Editor's pick
San Francisco Chronicle
8 November 2019
Bad science & bogus treatments

Misleading Ads About PrEP Are Threatening Progress to End the HIV Epidemic. They Must Be Removed.

Editor's pick
TheBodyPro
7 November 2019
PrEP policies & guidelines

United States Files Patent Infringement Lawsuit Against Gilead Related to Truvada® and Descovy® for Pre-exposure Prophylaxis of HIV

Editor's pick
U.S. Department of Health & Human Services
7 November 2019
PrEP programmes & uptake

PrEP services in France are changing in order to engage more people

News
7 November 2019
PrEP programmes & uptake

Polish PrEP activists creating services and building demand in a difficult environment

News
6 November 2019
Finance & funding

Some European governments are paying €3 a month for PrEP, while others are paying €850

News
5 November 2019
PrEP policies & guidelines

Lloyd Russell-Moyle MP: England must have full access to the drug that stops people getting HIV

Editor's pick
PoliticsHome
4 November 2019
PrEP science

Future PrEP Drugs, Delivery Methods, Technologies Target Adherence Issue

Editor's pick
American Journal of Managed Care
1 November 2019